Warby Parker Inc (WRBY)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $3.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Warby Parker Inc (WRBY) P/E Ratio & Valuation History
Warby Parker (WRBY) trades at 154.3x trailing earnings and 3.5x sales. Its P/S of 3.5x is above its 5-year median of 2.8x. Its forward P/E is 44.3x. The median P/E across 10 similar companies is 23.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 248.3% higher over the next year. Its free cash flow yield is 0.7%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 154.3x |
| Forward P/E | 44.3x |
| Price to sales | 3.5x |
| Price to book | 8.1x |
| EV/EBITDA | 51.3x |
| Price to FCF | 153.7x |
| EV/FCF | 140.1x |
| PEG | N/A |
| FCF yield | 0.7% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.5x | 2.8x | N/A |
| P/B | 8.1x | 6.6x | N/A |
Valuation History
Over the 3 of the 5 year ends shown that have a P/E, its P/E ranged from 90.8x in 2025 to 141.0x in 2023.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $21.79 | 90.8x | 3.1x | 7.3x |
| 2024 | $24.21 | 127.4x | 3.8x | 8.6x |
| 2023 | $14.10 | 141.0x | 2.5x | 5.5x |
| 2022 | $13.49 | N/A | 2.6x | 5.4x |
| 2021 | $46.56 | N/A | 2.7x | 18.3x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About WRBY
What is WRBY's forward P/E ratio?
Warby Parker has a forward P/E ratio of 44.3x.
Is WRBY stock overvalued?
GNG's valuation label for WRBY is Fairly valued. Its P/E of 154.3x compares with a median of 23.9x across 10 similar companies.
What is WRBY's price to sales ratio?
Warby Parker has a price to sales ratio of 3.5x.
WRBY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors